Breaking News Instant updates and real-time market news.

LEN

Lennar

$54.89

2.15 (4.08%)

, REGN

Regeneron

$471.67

11.76 (2.56%)

09:55
06/20/17
06/20
09:55
06/20/17
09:55

Early notable gainers among liquid option names on June 20th

Notable gainers among liquid option names this morning include Lennar (LEN) $55.48 +2.83, Regeneron (REGN) $484.23 +12.73, NVIDIA (NVDA) $161.46 +4.19, LabCorp (LH) $145.30 +3.48, and D R Horton (DHI) $34.66 +0.82.

LEN

Lennar

$54.89

2.15 (4.08%)

REGN

Regeneron

$471.67

11.76 (2.56%)

NVDA

Nvidia

$157.32

5.7 (3.76%)

LH

LabCorp

$144.36

2.465 (1.74%)

DHI

D.R. Horton

$34.75

0.9 (2.66%)

  • 20

    Jun

  • 22

    Jun

  • 26

    Jun

  • 15

    Aug

  • 29

    Aug

LEN Lennar
$54.89

2.15 (4.08%)

03/22/17
RBCM
03/22/17
NO CHANGE
RBCM
Lennar shares should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that Lennar reported "solid" Q1 results. He blames the stock's weakness on "reduced profitability due to higher costs for land and construction coupled with one-time expenses associated with the acquisition of WCI Communities (WCIC)." However, since Lennar reiterated its fiscal 2017 margin guidance and made upbeat comments about its outlook, the weakness was "unwarranted," according to Wetenhall. He raised his price target on the shares to $60 from $53 and keeps an Outperform rating on the stock.
05/16/17
MZHO
05/16/17
INITIATION
Target $59
MZHO
Buy
Lennar initiated with a Buy at Mizuho
Mizuho analyst Haendel St. Juste initiated Lennar with a Buy and a $59 price target.
04/13/17
RAJA
04/13/17
NO CHANGE
Target $60
RAJA
Strong Buy
Lennar added to 'Analyst Current Favorites' at Raymond James
Raymond James analyst Buck Horne added Lennar to the '"Analyst Current Favorites" list and raised its price target to $60, based on last week's S-11 filing from from Five Point Holdings which increases his sum-of-the-parts valuation for the company. Horne now seesnew evidence to suggest that his prior estimates regarding the value of Lennar's equity stake in Five Point was likely too conservative, at $5-6/share previously, versus $9+/share now, due to a larger than expected 45% equity interest in FPH and greater clarity around total entitlements and transaction activity. The analyst rates Lennar a Strong Buy.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
Barclays sees additiona near-term upside for builders
Barclays analyst Michael Dahl says his firm's February survey indicates "strong" early spring demand for U.S. homebuilders. Upcoming catalysts for the group will likely be positive, Dahl tells investors in a research note. The analyst sees "modest" further near-term upside for builder stocks despite the recent rallies. His Overweight rated names are PulteGroup (PHM), Lennar (LEN) and TRI Pointe (TPH). Dahl also believes D.R. Horton (DHI) is well positioned to capture incremental demand. He raised his price target for the shares to $34 from $30 but keeps an Equal Weight rating due to valuation.
REGN Regeneron
$471.67

11.76 (2.56%)

06/20/17
PIPR
06/20/17
NO CHANGE
Target $557
PIPR
Overweight
Piper says buy Regeneron on today's selloff, ups target to $557
Piper Jaffray analyst Edward Tenthoff recommends using today's weakness in shares of Regeneron Pharmaceuticals (REGN) after Novartis (NVS) reported positive Phase III data on brolucizumab as a buying opportunity. While brolucizumab is a competitive threat to Regeneron's Eylea, Novartis will not file until 2018 due to manufacturing issues, Tenthoff tells investors in a research note. He continues to expect Eylea sales growth of 6.1% to $3.52B this year and 5% to $3.7B in 2018 before brolucizumab hits the market in 2019. Tenthoff raised his price target for Regeneron Pharmaceuticals to $557 from $446 to reflect a higher price-to-earnings multiple and reiterates an Overweight rating on the shares. Positive Dupixent Phase III asthma data this fall would dramatically expand the company's market opportunity, he contends.
06/12/17
LEER
06/12/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron's Dupixent tracking well above consensus, says Leerink
Leerink analyst Geoffrey Porges says prescription trends suggest Regeneron (REGN) and Sanofi's (SNY) Dupixent will "comfortably exceed" current sell-side consensus expectations for this quarter and year. After 10 weeks, the prescription launch trajectory "remains very robust," Porges tells investors in a research note. The analyst views his Q2 sales estimate of $31M, versus the $16M consensus, as "reasonable," and feels full year sales of $200M-300M, versus the consensus of $135-$140M, is likely. He reiterates an Outperform rating on Regeneron shares.
05/23/17
JEFF
05/23/17
NO CHANGE
Target $418
JEFF
Hold
Regeneron approval expected, but positive, says Jefferies
Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.
05/05/17
LEER
05/05/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron price target raised to $493 from $448 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $493 from $448 following quarterly results, and given the strength of peer company multiples and greater conviction about long-term profitability. The analyst reiterates an Outperform rating on the shares.
NVDA Nvidia
$157.32

5.7 (3.76%)

06/20/17
PACS
06/20/17
DOWNGRADE
PACS
Sector Weight
ON Semiconductor downgraded to Sector Weight from Overweight at Pacific Crest
Pacific Crest analyst Michael McConnell downgraded ON Semiconductor (ON) to Sector Weight after Asia supply-chain channel checks left him "incrementally more cautious." Signs of double-ordering by customers raises risk of a correction over the next 12 months, McConnell tells investors in a research note. He recommends investors move to the sidelines with respect to the shares. The analyst this morning also upgraded Nvidia (NVDA) to Sector Weight and Marvell Technology (MRVL) to Overweight.
06/20/17
PACS
06/20/17
UPGRADE
PACS
Sector Weight
Nvidia upgraded to Sector Weight from Underweight at Pacific Crest
Pacific Crest analyst Michael McConnell upgraded Nvidia to Sector Weight after Asia supply-chain channel checks left him "incrementally more positive." Strong GPU demand from the cryptocurrency mining market has "rapidly depleted excess channel inventory" carried into Q2 and reduces gaming segment growth concerns in FY18, McConnell tells investors in a research note.
06/15/17
RAJA
06/15/17
INITIATION
Target $175
RAJA
Outperform
Nvidia resumed with an Outperform at Raymond James
Raymond James analyst Chris Caso resumed coverage on Nvdia with an Outperform and a $175 price target saying valuation is being driven by long-term Datacenter and Auto potential and shares should continue higher if those segments continue to advance and the core business remains stable.
06/15/17
WELS
06/15/17
NO CHANGE
WELS
Nvidia likely to encounter competition in accelerators, says Wells Fargo
Wells Fargo believes that "several different classes of (datacenter) accelerators" will emerge. The firm says that Nvidia's accelerators "are optimized for some specific types of applications" i.e. graphics or image processing,leaving the door open for processors that are stronger in other areas. Wells keeps an Underperform rating on Nvidia.
LH LabCorp
$144.36

2.465 (1.74%)

02/06/17
BARD
02/06/17
DOWNGRADE
Target $138
BARD
Neutral
LabCorp downgraded to Neutral at Baird
As previously reported, Baird analyst Whit Mayo downgraded LabCorp to Neutral from Outperform as he is less convinced the company can grow earnings double digits in 2017, the current valuation is above historical averages, and he does not see an M&A deal that would meaningfully alter the risk/reward. Mayo has a $138 price target on LabCorp shares.
05/09/17
JEFF
05/09/17
NO CHANGE
Target $66
JEFF
Hold
Parexel sale best way to fix company, says Jefferies
Jefferies analyst David Windley believes a sale of Parexel (PRXL), which the Wall Street Journal reported yesterday is under consideration, is "likely the best way to fix the company for many reasons." Parexel has been suggested as one of LabCorp's (LH) interests, but LabCorp management may not want to take on such a deal, Windley tells investors in a research note. Parexel changes are more easily undertaken in private, he contends. The analyst has a Hold rating on the shares with a $66 price target.
02/06/17
02/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AutoNation (AN) downgraded to Hold from Buy at Evercore ISI with analyst Michael Montani saying calendar year 2017 is shaping up to be an investment year and reduced estimates. The analyst said the AutoNation USA brand extension strategy means fewer franchised acquisitions and more pre-open expense for this year and next. 2. LabCorp (LH) downgraded to Neutral from Outperform at Baird with analyst Whit Mayo saying he is less convinced the company can grow earnings double digits in 2017, the current valuation is above historical averages, and he does not see an M&A deal that would meaningfully alter the risk/reward. 3. Tiffany (TIF) downgraded to Neutral from Buy at Mizuho and to Hold from Buy at HSBC. 4. CVS Health (CVS) downgraded to Neutral from Overweight at Atlantic Equities. 5. NVIDIA (NVDA) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying he "struggles" to articulate a valuation-driven for the stock meaningfully above current trading levels. Nonetheless, the analyst expects another "outstanding result" when the company announces earnings this week. He raised his price target on the shares to $120 from $95. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/17/17
ADAM
02/17/17
NO CHANGE
Target $150
ADAM
Buy
LabCorp price target raised to $150 from $140 at Canaccord
Canaccord analyst Mark Massaro raised his price target on LabCorp to $150 from $140 following better than expected Q4 results. The analysts feels the company guidance is set appropriately and that shares are cheap. Massaro said it remains one of his top five picks, citing the potential for improving multiple expansion and solid free cash flow. Massaro reiterated his Buy rating on LabCorp shares.
DHI D.R. Horton
$34.75

0.9 (2.66%)

04/21/17
RBCM
04/21/17
NO CHANGE
RBCM
D.R. Horton should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that D.R. Horton reported "strong" Q2 results, The analyst raised his price target on the stock to $37 from $35 and keeps an Outperform rating on the shares. He recommends buying the shares on weakness.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
D.R. Horton acquisition of Forestar Group would be positive, says Wells Fargo
After D.R. Horton (DHI) made an unsolicited bid for Forestar Group (FOR), Wells Fargo says that acquiring Forestar would enable D.R. Horton "to grow at a double digit rate while mitigating incremental risk." The analyst says that the deal would give D.R. Horton "a solid competitive advantage" and enable it to grow more quickly while "mitigating potential impairment risk through the cycle." Wells thinks that D.R. Horton will enter into a "bidding war" with Starwood Capital, which had previously agreed to take Forestar private for $14 per share. Wells keeps an Outperform rating on D.R. Horton.
04/21/17
WELS
04/21/17
NO CHANGE
WELS
D.R. Horton weakness overdone, says Wells Fargo
After D.R. Horton provided lower than expected 2H17 revenue guidance and the stock sank, Wells Fargo says the company reported many strong data points. It says that the company's outlook remains positive, and it recommends buying the shares on weakness.
05/16/17
MZHO
05/16/17
INITIATION
Target $32
MZHO
Neutral
D.R. Horton initiated with a Neutral at Mizuho
Mizuho analyst Haendel St. Juste initiated D.R. Horton with a Neutral and a $32 price target.

TODAY'S FREE FLY STORIES

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

, ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

20:04
09/24/17
09/24
20:04
09/24/17
20:04
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

ORCL

Oracle

$48.16

0.19 (0.40%)

GPRO

GoPro

$10.75

-0.19 (-1.74%)

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

SIX

Six Flags

$58.96

1.14 (1.97%)

HMC

Honda

$29.91

0.18 (0.61%)

IRBT

iRobot

$76.14

-3.8 (-4.75%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 28

    Sep

  • 12

    Oct

  • 24

    Oct

  • 08

    Nov

  • 12

    Jan

NVCR

Novocure

$21.50

-0.1 (-0.46%)

18:27
09/24/17
09/24
18:27
09/24/17
18:27
Hot Stocks
Combination of Novocure Optune with Temozolomide demonstrates five-year survival »

Novocure announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$102.40

-0.09 (-0.09%)

, CMCSA

Comcast

$38.10

0.63 (1.68%)

17:10
09/24/17
09/24
17:10
09/24/17
17:10
Hot Stocks
Box Office Battle: 'Kingsman: The Golden Circle' easily wins weekend »

"Kingsman: The…

TWX

Time Warner

$102.40

-0.09 (-0.09%)

CMCSA

Comcast

$38.10

0.63 (1.68%)

CMCSK

Comcast

SNE

Sony

$37.50

0.04 (0.11%)

FOX

21st Century Fox

$26.43

0.1 (0.38%)

FOXA

21st Century Fox

$26.88

0.12 (0.45%)

LGF.A

Lionsgate

$31.49

0.24 (0.77%)

DIS

Disney

$98.60

-0.29 (-0.29%)

VIAB

Viacom

$27.64

0.24 (0.88%)

VIA

Viacom

$38.00

-0.2 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

16:41
09/24/17
09/24
16:41
09/24/17
16:41
Periodicals
Amazon affiliate to buy stake in Indian retailer Shoppers Stop, Reuters says »

An affiliate of Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

16:37
09/24/17
09/24
16:37
09/24/17
16:37
Periodicals
Internet giants on the defensive in Washington, Reuters says »

Internet giants,…

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

, UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

16:25
09/24/17
09/24
16:25
09/24/17
16:25
Periodicals
Opposition to new 'Obamacare' repeal bill grows, Reuters reports »

The new proposal by…

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

CNC

Centene

$92.22

1.48 (1.63%)

WCG

WellCare

$167.16

1.1 (0.66%)

CI

Cigna

$182.74

0.61 (0.33%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

AET

Aetna

$153.57

0.18 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

SAP

SAP

$110.27

0.64 (0.58%)

16:11
09/24/17
09/24
16:11
09/24/17
16:11
Hot Stocks
SAP announces acquisition of Gigya »

SAP has announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATT

TAT Technologies

$10.70

0.05 (0.47%)

, BA

Boeing

$256.45

0.41 (0.16%)

16:03
09/24/17
09/24
16:03
09/24/17
16:03
Hot Stocks
TAT Technologies awarded APU MRO contract for fleet of Boeing, Airbus »

TAT Technologies (TATT),…

TATT

TAT Technologies

$10.70

0.05 (0.47%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.